SOURCE: BioMedReports


February 10, 2010 09:41 ET

Rexahn Pharmaceuticals (Amex: RNN): An Undiscovered Biotech With Multiple Catalysts Poised to See Significant Price Moves in the Short Term

LOS ANGELES, CA--(Marketwire - February 10, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Rexahn Pharmaceuticals (NYSE Amex: RNN) has gone almost completely undiscovered by most investors in the space of thousands of publicly traded biotechnology and health care companies. Until now.

In short, this is a clinical stage biopharmaceutical company trading under a dollar on a major exchange, with multiple catalysts to help its share price move significantly higher in the short term (this quarter). The potential of the treatments and drugs in the company's pipeline include three drugs that analysts have labled "potential blockbusters" that have several big pharmaceutical companies lining up as interested partners.

In fact, already one partner -- Teva Pharmaceuticals -- signed a development & commercialization agreement for RX-3117, a novel anti-cancer compound last September.

RNN also has "multi-indication" therapeutics that positions it for long-term success. Their three market leading compounds have all shown excellent safety profiles.

A complete report on the company with quotes from its CEO and founder, Dr. Chang Ahn is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556